D8517
鉄-デキストラン
95-105 mg/mL (Iron content), solution
別名:
水酸化第二鉄デキストラン複合体
SMILES string
[Fe].[S](=O)(=O)(O)O
InChI
1S/Fe.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)
InChI key
MVZXTUSAYBWAAM-UHFFFAOYSA-N
biological source
synthetic
sterility
aseptically filled
assay
95-105 mg/mL (Iron content)
form
solution
contains
0.5% phenol as preservative
composition
Iron, ~100 mg/mL
color
brown
useful pH range
4 - 6.5
storage temp.
room temp
Quality Level
signalword
Danger
hcodes
Hazard Classifications
Carc. 1B - Skin Sens. 1
保管分類
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
名称等を表示すべき危険物及び有害物
ishl_indicated
名称等を通知すべき危険物及び有害物
ishl_notified
D8517-BULK: + D8517PROC: + D8517-PPG: + D8517-25ML-PW: + D8517-100ML-PW: + D8517-VAR: + D8517-100ML:4548174008478 + D8517-25ML:4548174008485 + D8517-PH:
jan
Laura Nigi et al.
Frontiers in endocrinology, 11, 630-630 (2020-10-13)
C-X-C Motif Chemokine Ligand 10 (CXCL10) is a pro-inflammatory chemokine specifically recognized by the ligand receptor CXCR3 which is mostly expressed in T-lymphocytes. Although CXCL10 expression and secretion have been widely associated to pancreatic islets both in non-obese diabetic (NOD)
Alejandro Martin-Malo et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 27(6), 2465-2471 (2011-12-31)
This study analysed, in vivo and in vitro, the effects of four different intravenous iron preparations (iron gluconate, iron sucrose, iron dextran and ferric carboxymaltose) on activation and damage of mononuclear cells. A randomized prospective study was conducted in 10
S Fishbane et al.
Seminars in dialysis, 13(6), 381-384 (2000-12-29)
Intravenous iron treatment is an important component of anemia therapy for patients on dialysis. Until recently iron dextran was the only parenteral form of iron available in the United States. This drug has been associated with occasional serious adverse reactions
Xiao Chai et al.
Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 35(5), 547-552 (2013-11-05)
To establish a mouse model of iron overload by intraperitoneal injection of iron dextran and investigate the impact of iron overload on bone marrow hematopoiesis. A total of 40 C57BL/6 mice were divided into control group, low-dose iron group (12.5
D L Burns et al.
Nutrition (Burbank, Los Angeles County, Calif.), 11(2), 163-168 (1995-03-01)
Iron dextran was introduced more than 30 yr ago for the parenteral treatment of iron deficiency anemia that is refractory to oral therapy. Iron dextran is a preparation of ferric hydroxide complexed with a low molecular weight fraction of dextran.
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）